PEDIATRICS Vol. 106 No. 5 November 2000, pp. 989-997
A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents
Received Aug 6, 1999; accepted Feb 1, 2000.
,
,
From the * Palm Beach Headache Center, West Palm Beach, Florida;
Cleveland Clinic, Cleveland, Ohio; § Michigan Headache and
Neurological Institute, Ann Arbor, Michigan; San Antonio Center for
Clinical Research, San Antonio, Texas; and ¶ Glaxo Wellcome Inc,
Research Triangle Park, North Carolina.
Objective. To compare the efficacy and tolerability of sumatriptan nasal spray (NS; 5 mg, 10 mg, and 20 mg) with placebo for the treatment of acute migraine in adolescents.
Methods. A randomized, double-blind, placebo-controlled, single-attack study was conducted in 653 US adolescents (12-17 years of age). Patients with at least a 6-month history of migraine, who met International Headache Society criteria for migraine (with or without aura) were eligible for participation. Headache relief 2 hours postdose, complete relief, presence or absence of associated symptoms, headache recurrence, and use of rescue medications were recorded. The primary efficacy endpoint was headache relief 2 hours postdose sumatriptan NS (20 mg) versus placebo. Safety and tolerability were assessed by examining adverse events, changes in electrocardiograms, vital signs, physical examinations, and clinical laboratory tests.
Results. Headache relief 1 hour postdose was significantly greater for patients using 10 mg (56%) and 20 mg (56%) of sumatriptan NS compared with placebo (41%). Headache relief 2 hours postdose was significantly greater for patients using 5 mg of sumatriptan NS (66%) compared with placebo (53%), and approached statistical significance for 20 mg (63%) compared with placebo (53%). Complete relief 2 hours postdose was significantly greater for patients using 20 mg of sumatriptan NS compared with placebo (36% vs 25%, respectively). Each dose of sumatriptan (5 mg, 10 mg, and 20 mg) was superior to placebo with respect to the cumulative percentages of patients first reporting headache relief within 2 hours of dosing (Kaplan-Meier). The sumatriptan 20-mg dose was superior to placebo with respect to the cumulative percentages of patients first reporting complete relief within 2 hours of dosing (Kaplan-Meier). Photophobia and phonophobia were significantly reduced 2 hours postdose for sumatriptan NS (20 mg), compared with placebo (36% vs 48% and 25% vs 44%, respectively). Taste disturbance was the most commonly reported adverse event (2%, 19%, 30%, and 26% for placebo, 5 mg, 10 mg, and 20 mg, respectively). No drug-related serious adverse events or clinically relevant changes in laboratory parameters, electrocardiograms, or vital signs were reported.
Conclusions. Sumatriptan NS is effective and well-tolerated for the treatment of acute migraine in adolescents, with the 20-mg dose providing the best overall efficacy and tolerability profiles. Key words: migraine, sumatriptan, adolescents, pediatric.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  R W Newton Childhood headache Arch. Dis. Child. Ed. Pract., August 1, 2008; 93(4): 105 - 111. [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Lewis, P. Winner, A. D. Hershey, W. W. Wasiewski, and on behalf of the Adolescent Migraine Steering Comm Efficacy of Zolmitriptan Nasal Spray in Adolescent Migraine Pediatrics, August 1, 2007; 120(2): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ryan Medicines for migraine Arch. Dis. Child. Ed. Pract., April 1, 2007; 92(2): ep50 - ep55. [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Lewis Pediatric Migraine Pediatr. Rev., February 1, 2007; 28(2): 43 - 53. [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Benjamin Jr, P. B. Smith, M. D. Murphy, R. Roberts, L. Mathis, D. Avant, R. M. Califf, and J. S. Li Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA, September 13, 2006; 296(10): 1266 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Evers, A. Rahmann, C. Kraemer, G. Kurlemann, O. Debus, I. W. Husstedt, and A. Frese Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen Neurology, August 8, 2006; 67(3): 497 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N P Barnes and S Jayawant MIGRAINE Arch. Dis. Child. Ed. Pract., October 1, 2005; 90(3): ep53 - ep57. [Full Text] [PDF]
|
|
|
|
|
|
L. Damen, J. K.J. Bruijn, A. P. Verhagen, M. Y. Berger, J. Passchier, and B. W Koes Symptomatic Treatment of Migraine in Children: A Systematic Review of Medication Trials Pediatrics, August 1, 2005; 116(2): e295 - e302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Hershey and P. K. Winner Pediatric Migraine: Recognition and Treatment J Am Osteopath Assoc, April 1, 2005; 105(4_suppl): 2S - 8S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lewis, S. Ashwal, A. Hershey, D. Hirtz, M. Yonker, and S. Silberstein Practice Parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society Neurology, December 28, 2004; 63(12): 2215 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Managing migraine in children DTB, April 1, 2004; 42(4): 25 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Christensen, R. K. Mottern, J. T. Jabbour, and E. Fuseau Pharmacokinetics of Sumatriptan Nasal Spray in Children J. Clin. Pharmacol., April 1, 2004; 44(4): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ahonen, M. L. Hamalainen, H. Rantala, and K. Hoppu Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial Neurology, March 23, 2004; 62(6): 883 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Landy Migraine throughout the life cycle: Treatment through the ages Neurology, March 9, 2004; 62(90052): S2 - 8. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Pakalnis, D. Kring, and J. Paolicchi Parental Satisfaction With Sumatriptan Nasal Spray in Childhood Migraine J Child Neurol, November 1, 2003; 18(11): 772 - 775. [Abstract] [PDF]
|
|
|
|
|
|
M. L. Christensen, R. K. Mottern, J. T. Jabbour, and E. Fuseau Pharmacokinetics of Sumatriptan Nasal Spray in Adolescents J. Clin. Pharmacol., July 1, 2003; 43(7): 721 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Powers, S. R. Patton, K. A. Hommel, and A. D. Hershey Quality of Life in Childhood Migraines: Clinical Impact and Comparison to Other Chronic Illnesses Pediatrics, July 1, 2003; 112(1): e1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Berde and N. F. Sethna Analgesics for the Treatment of Pain in Children N. Engl. J. Med., October 3, 2002; 347(14): 1094 - 1103. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Fenster; and P. Winner Migraine Treatment Pediatrics, September 1, 2001; 108(3): 817 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Sumatriptan Nasal Spray for Adolescents with Migraines Journal Watch Emergency Medicine, January 31, 2001; 2001(131): 5 - 5. [Full Text]
|
|
|
|
 |
|
 Sumatriptan for Adolescent Migraine Journal Watch (General), November 10, 2000; 2000(1110): 5 - 5. [Full Text]
|
|
